IceCure's ICE3 5-Year Trial Results Published In The Peer Reviewed Annals Of Surgical Oncology Journal: ProSense Cryoablation Without Excision For Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical Ltd. (NASDAQ: ICCM) announced the publication of its ICE3 trial results in the Annals of Surgical Oncology, showing a 96.3% recurrence-free rate for early-stage, low-risk breast cancer treated with ProSense cryoablation. The publication precedes an FDA Advisory Panel Meeting for marketing authorization of ProSense, scheduled for November 7, 2024.
September 24, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical's ICE3 trial results show a 96.3% recurrence-free rate for early-stage breast cancer using ProSense cryoablation. The results are published ahead of an FDA Advisory Panel Meeting for marketing authorization, which could significantly impact the company's market position and stock price.
The publication of the ICE3 trial results in a peer-reviewed journal highlights the effectiveness of IceCure's ProSense cryoablation technology, which could lead to increased adoption and market share. The upcoming FDA Advisory Panel Meeting is crucial for obtaining marketing authorization, which would likely boost investor confidence and positively impact ICCM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100